- Home
- A-Z Publications
- Current Medicinal Chemistry
- Previous Issues
- Volume 12, Issue 15, 2005
Current Medicinal Chemistry - Volume 12, Issue 15, 2005
Volume 12, Issue 15, 2005
-
-
Antiretroviral Compounds: Mechanisms Underlying Failure of HAART to Eradicate HIV-1
More LessDuring the past decade, combined highly active antiretroviral therapy (HAART) consisting of the nucleoside, non-nucleoside and protease inhibitors has improved the outlook for HIV-infected individuals. However, despite the clinical improvement associated with HAART, current antiviral drug regimens are not able to eradicate HIV due to the persistence of virus in cellular reservoirs (predominantly long-lived memory CD4+ T c Read More
-
-
-
Derivatives as 5HT1A Receptor Ligands-Past and Present
Authors: G. Caliendo, V. Santagada, E. Perissutti and F. FiorinoSerotonin is a neuromediator, well-know for its implication in mood regulation, anxiety, depression and, insomnia as well as in normal human function such as sleep, sexual activity and appetite. In this way, serotonin (5-hydroxytryptamine, 5-HT) is one of the most attractive targets for medicinal chemists and pharmaceutical companies. Among 5-HTRs, the 5-HT1A subtype is the best studied, and it is generally accepted Read More
-
-
-
New Trends in Anti-Atherosclerotic Agents
Authors: C. Napoli, V. Sica, O. Pignalosa and F. d. NigrisNew approaches to atherosclerosis-related diseases include novel uses of proven treatments and development of innovative agents. Several commonly used cardiovascular drugs such as dihydropyridine calcium antagonists, ACE inhibitors containing the sulphydryl group, or highly lipophilic beta-blockers have some antiatherosclerotic activities. Moreover, new clinical trials suggesting that additional reduction of lowd Read More
-
-
-
Receptor Tyrosine Kinases as Targets for Anticancer Therapeutics
Authors: Francesca Carlomagno and Massimo SantoroOncogenic conversion of receptor protein tyrosine kinases (RTK) is a frequent feature of malignant cells. This knowledge has fostered efforts to develop target-specific low molecular weight therapeutics able to obstruct RTK signalling. The clinical efficacy of the ABL- and KIT-inhibitors are paradigmatic of the power of this approach. Here, we focus on small-molecule inhibitors for RTKs involved in human cancer. In particula Read More
-
-
-
Dendritic Cells: Activation and Maturation - Applications for Cancer Immunotherapy
Authors: Kuo-Ching Sheng, Geoff A. Pietersz, Mark D. Wright and Vasso ApostolopoulosThere is an increasing number of studies utilizing dendritic cell (DC) based therapies for cancer. With a powerful antigen-presentation capability, DCs have the potential to overcome tumor tolerance and induce anti-tumor immunity, when loaded with tumor antigens. In order to optimize this approach, methods have aimed to enhance immunopotency of therapeutic DCs. A thorough understanding of DC immunobiology would Read More
-
-
-
Drug Targets in Stress-Related Disorders
Authors: Vito Covelli, Maria E. Passeri, Domenica Leogrande, Emilio Jirillo and Luigi AmatiNervous and immune systems mutually cooperate via release of mediators of both neurological and immunological derivation. Adrenocorticotropin hormone (ACTH) is a product of the hypothalamus-pituitary adrenal axis (HPAA) which stimulates secretion of corticosteroids from adrenals. In turn, corticosteroids modulate the immune response in virtue of their anti-inflammatory activity. On the other hand, catecholamines, product Read More
-
-
-
Anti-HIV Activities of Natural Antioxidant Caffeic Acid Derivatives: Toward an Antiviral Supplementation Diet
Authors: Fabrice Bailly and Philippe CotelleSince 1996, highly active antiretroviral therapy (HAART) was designed to rapidly control HIV replication. It has had a significant impact on patient health and progression of AIDS in developed countries, but its success has not been complete. HAART strategy still suffers from issues of patient compliance, cost, deleterious side effects and emerging drug resistance. Therefore, expansion of novel anti-HIV drugs and targets will b Read More
-
Volumes & issues
-
Volume 32 (2025)
-
Volume 31 (2024)
-
Volume 30 (2023)
-
Volume 29 (2022)
-
Volume 28 (2021)
-
Volume 27 (2020)
-
Volume 26 (2019)
-
Volume 25 (2018)
-
Volume 24 (2017)
-
Volume 23 (2016)
-
Volume 22 (2015)
-
Volume 21 (2014)
-
Volume 20 (2013)
-
Volume 19 (2012)
-
Volume 18 (2011)
-
Volume 17 (2010)
-
Volume 16 (2009)
-
Volume 15 (2008)
-
Volume 14 (2007)
-
Volume 13 (2006)
-
Volume 12 (2005)
-
Volume 11 (2004)
-
Volume 10 (2003)
-
Volume 9 (2002)
-
Volume 8 (2001)
-
Volume 7 (2000)
Most Read This Month
Article
content/journals/cmc
Journal
10
5
false
en
